Muhammed Kashif Riaz

Muhammed Kashif Riaz

Auto-generated profile, based on publicly available information

Muhammed Kashif Riaz

University of Cincinnati 1 Cincinnati, OH

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
SGShuchi Gulati
Shuchi Gulati
JDJanki Mihir Desai
Janki Mihir Desai
SPSarah M. Palackdharry
Sarah M. Palackdharry
JMJohn C. Morris
John C. Morris
ZZZheng Zhu
Zheng Zhu
TWTrisha Wise-Draper
Trisha Wise-Draper

21 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SGShuchi Gulati
Shuchi Gulati
MCMcKenzie Crist
McKenzie Crist
MRMuhammed Kashif Riaz
Muhammed Kashif Riaz
VTVinita Takiar
Vinita Takiar
MLMaria Lehn
Maria Lehn
TWTrisha Wise-Draper
Trisha Wise-Draper
Purpose: The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and suppression of antitumor immunity. We hypothesized that adding an immune-checkpoint inhibitor (ICI) could overcome this and lead to an enhanced antitumor response. Patients and Methods: A phase II study of cetuximab and durvalumab in metastatic HNSCC was conducted. Eligible patients had measurable disease. Patients who had received both cetuximab and an ICI were excluded. The primary endpoint was objective response rate (ORR) by RECIST 1.1 at 6 months. Results: As of April 2022, 35 patients enrolled, of whom 33 received at least 1 dose of durvalumab and were included in the response analysis. Eleven patients (33%) had received prior platinum-based chemotherapy, 10 an ICI (30%), and 1 patient (3%) cetuximab. ORR was 39% (13/33) with a median duration of response of 8.6 months [95% confidence interval (CI): 6.5–16.8]. Median progression-free and overall survivals were 5.8 months (95% CI: 3.7–14.1) and 9.6 months (95% CI: 4.8–16.3), respectively. There were 16 grade 3 treatment-related adverse events (TRAE) and one grade 4 TRAE, with no treatment-related deaths. Overall and progression-free survival did not correlate with PD-L1 status. NK cell cytotoxic activity was increased by cetuximab and further increased with the addition of durvalumab in responders. Conclusions: The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.

1 June 2025 in Cancer Research Communications
Verified
Journal Article
Open access
OZOlga Zamulko
Olga Zamulko
VKVidhya Karivedu
Vidhya Karivedu
MRMuhammad Kashif Riaz
Muhammad Kashif Riaz
IMIlaina Monroe
Ilaina Monroe
ARAudrey Romano
Audrey Romano
TWTrisha Wise-Draper
Trisha Wise-Draper
Purpose: Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) portends a poor prognosis. DNA pathway repair mutations in HNSCC are associated with higher tumor mutational burden rates and immune checkpoint inhibitor response. PARP inhibitors (PARPi) induce ssDNA breaks and are efficacious in cancers with DNA repair defects. Thus, we designed a single-arm, open-label, phase II clinical trial to evaluate the combination of niraparib and dostarlimab in patients with R/M HNSCC. Patients and Methods: Patients with R/M HNSCC were treated with niraparib and dostarlimab until disease progression or unacceptable toxicity. The primary endpoint was the overall response rate and clinical benefit assessed by RECIST version 1.1. Using Simon’s two-step minimax design, 14 patients were planned to enroll in the first stage with a goal of overall clinical benefit of 50%. Results: Ten patients were enrolled. The majority were White males with a median age of 62.5. One patient had a PD-L1 combined positive score >20, a high tumor mutational burden, a BRCA1 rearrangement, and an ATRX splice site mutation. Nine patients previously failed anti–PD-1/PD-L1 therapy. The best overall response rate was 10%, with a 20% clinical benefit (1 partial response, 1 stable disease). The trial was terminated early for futility as the goal clinical benefit could not be reached. At a median follow-up of 10.13 months, the median progression-free survival was 3.8 months, and the median overall survival was 10.1 months. The most common grade 3 or higher treatment-related adverse events were thrombocytopenia and hypertension. Conclusions: The combination of niraparib and dostarlimab did not achieve the primary endpoint of clinical benefit, but activity may be improved with biomarker-driven treatment and selected patients. Significance: Patients with R/M HNSCC that progress on PD-1 inhibitors have poor prognoses. PARPis cause ssDNA breaks that accumulate in cells with mutations in DNA damage repair pathways, leading to synthetic lethality. However, PARPi also inhibits glycogen synthase kinase-3β activity, leading to upregulated PD-L1, which is abrogated by PD-1 inhibitors. In this study, we combine niraparib (PARPi) with dostarlimab (anti–PD-L1) to evaluate clinical benefit in patients with R/M HNSCC.